Rinvoq is a medicine for several immune conditions, including arthritis, eczema, Crohn's disease and ulcerative colitis. It is taken as a pill or a liquid by mouth. It works by calming parts of the immune system that cause swelling and irritation.
Every report comes from a Lived member, sent anonymously.
Have you tried Rinvoq (Upadacitinib) for Rheumatoid Arthritis?
Upadacitinib, sold as Rinvoq, is a prescription pill for several long-term inflammatory diseases in which the immune system attacks the body's own tissues. In adults it is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (inflammatory arthritis of the spine that does not yet show damage on X-rays), ulcerative colitis, Crohn's disease and giant cell arteritis, an inflammation of large arteries that mainly affects older adults. It is also approved for moderate to severe eczema (atopic dermatitis) in adults and children 12 and older. Children 2 and older can take it for polyarticular juvenile idiopathic arthritis (arthritis in five or more joints) and psoriatic arthritis, and Rinvoq LQ, a liquid form, is available for younger or smaller children. Rinvoq is usually not a first treatment. For the arthritis and bowel conditions, it is approved for people whose disease stayed active on at least one tumor necrosis factor (TNF) blocker, part of a widely used family of biologic anti-inflammatory medicines, or who could not tolerate one. In ulcerative colitis and Crohn's disease, people who cannot use a TNF blocker may qualify after another approved whole-body treatment. For eczema, it is meant for people whose skin was not controlled by other whole-body treatments, including biologics, or who cannot use them. Giant cell arteritis is the exception: there, Rinvoq is used alongside a tapering course of steroids, with no requirement to try a TNF blocker first.
In these diseases, immune cells keep exchanging chemical messengers called cytokines that drive inflammation in the joints, gut, skin or blood vessels. When a cytokine attaches to a cell, enzymes inside the cell called Janus kinases (JAKs) pass the message along, switching on genes that keep the inflammatory response going. Upadacitinib is a JAK inhibitor: it blocks those enzymes, so several inflammatory signals are dampened at once. That breadth helps explain both its benefits and its risks. The same signaling pathways help the body fight infection and make blood cells, which is why infections and changes in blood counts are among its main concerns. Upadacitinib acts more strongly on some JAK enzymes than others, but it is not known how much that selectivity matters for how well it works.
Rinvoq is an extended-release tablet taken once a day, with or without food. It must be swallowed whole, never split, crushed or chewed. Most conditions use 15 mg a day. For eczema, the prescriber may raise the dose to 30 mg if 15 mg is not enough, although people 65 and older stay at 15 mg. Ulcerative colitis and Crohn's disease start with a short, higher-dose phase (45 mg for 8 or 12 weeks respectively), then step down to a lower ongoing dose of 15 mg, or 30 mg for severe or extensive disease. In giant cell arteritis, Rinvoq is taken together with a steroid course that is gradually tapered, and can then continue on its own. Rinvoq LQ, the liquid, is given twice a day with an oral syringe, at a dose based on the child's weight. The liquid and the tablets are not interchangeable milligram for milligram, so any switch between them should be made by the prescriber. Before the first dose, the care team usually tests for tuberculosis and hepatitis B and C, checks blood counts and liver function, confirms pregnancy status where relevant, and brings vaccines up to date, including the shingles vaccine.
The most common side effects are colds and other upper respiratory infections, nausea, cough, headache, fever and acne. Cold sores and shingles (a painful, blistering rash, usually on one side of the body) are more common than usual because the drug weakens some immune defenses. Blood tests may show lower white or red blood cell counts, higher cholesterol, raised liver enzymes or a raised level of creatine phosphokinase, a muscle enzyme. These usually cause no symptoms and are found on routine monitoring. Because infections can become serious, call the prescriber right away for fever or chills, a new cough or shortness of breath, warm, red or painful skin, burning when urinating, or a blistering rash. New stomach pain with fever, chills or vomiting needs prompt medical attention. In rare cases the wall of the stomach or bowel can tear, mostly in people who have had diverticulitis or who also take steroids or anti-inflammatory painkillers. Severe allergic reactions are rare: stop taking Rinvoq and get emergency help for trouble breathing or swelling of the lips, tongue or throat.
Rinvoq's label carries a boxed warning covering several serious risks. It raises the chance of serious infections, including tuberculosis, fungal infections and the return of a past hepatitis B infection, some of which have led to hospitalization or death. Most of these infections in studies occurred in people also taking methotrexate (an immune-suppressing arthritis drug) or steroids, and serious infections were more frequent at 30 mg than at 15 mg. Tuberculosis testing is repeated during treatment even after a negative first test, and Rinvoq is paused during a serious infection. The boxed warning also reflects a large safety study of another JAK inhibitor in people with rheumatoid arthritis aged 50 or older with at least one heart risk factor. Compared with TNF blockers, that drug led to more deaths, heart attacks and strokes, cancers (including lymphoma, and lung cancer in smokers) and blood clots in the legs and lungs, with current and former smokers at greatest risk. Lymphoma, other cancers and blood clots have also occurred with Rinvoq itself. These findings weigh most for older adults, smokers and anyone with heart disease, past blood clots or a history of cancer, and Rinvoq is stopped after a heart attack or stroke. Stop taking Rinvoq and get emergency help for signs of a heart attack, stroke or blood clot, such as chest pain or pressure, weakness on one side of the body, slurred speech, a swollen, painful leg or sudden shortness of breath. Skin cancers have been reported as well, so sun protection and regular skin checks are advised for people at higher risk. Rinvoq is not combined with other JAK inhibitors, biologics or strong immune suppressants such as azathioprine and cyclosporine, and it is not recommended for people with severe liver impairment. Avoid grapefruit and grapefruit juice: like ketoconazole (an antifungal) and clarithromycin (an antibiotic), grapefruit raises upadacitinib levels in the blood, and some doses are lowered when such drugs are needed. Rifampin, a tuberculosis antibiotic, lowers levels and can make Rinvoq less effective. Live vaccines should be avoided during treatment. Low blood sugar, sometimes severe, has been reported after starting Rinvoq and other JAK inhibitors in people with diabetes, so they may need closer blood sugar checks and should tell their care team about any signs of low blood sugar. Animal studies suggest upadacitinib may harm a developing baby. People who could become pregnant should use effective birth control during treatment and for 4 weeks after the last dose. Breastfeeding is not recommended during treatment and for 6 days after the last dose.
How quickly Rinvoq helps depends on the condition. Arthritis and eczema trials judged results at 12 to 16 weeks, while in ulcerative colitis some people improved within 2 weeks of starting the 45 mg dose. In eczema trials, roughly 40 to 50 percent of people on 15 mg, and more on 30 mg, had clear or almost clear skin at 16 weeks, compared with fewer than 1 in 10 on placebo. In ulcerative colitis, about a quarter to a third were in remission after 8 weeks, compared with about 1 in 20 on placebo. In giant cell arteritis, Rinvoq with a 26-week steroid taper kept more people in remission without steroids through one year than a 52-week steroid taper alone. Not everyone responds, and in the bowel diseases Rinvoq is stopped if the higher maintenance dose does not work. Treatment comes with regular blood tests: blood counts and liver enzymes from time to time, and a cholesterol check about 12 weeks after starting. Rinvoq controls inflammation while it is taken but does not cure these conditions, so treatment is usually ongoing, with the prescriber reweighing benefits and risks over time. People with an ostomy or a shortened bowel occasionally see tablet remnants in their stool or ostomy output; this is worth reporting if it keeps happening, because the medicine may not be working as well.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Rinvoq (Upadacitinib), what you've noticed, or ask the community a question.